RT Journal Article
T1 Decreased plasma concentrations of BDNF and IGF-1 in abstinent patients with alcohol use disorders.
A1 Garcia-Marchena, Nuria
A1 Silva-Peña, Daniel
A1 Martin-Velasco, Ana Isabel
A1 Villanua, Maria Angeles
A1 Araos, Pedro
A1 Pedraz, Maria
A1 Maza-Quiroga, Rosa
A1 Romero-Sanchiz, Pablo
A1 Rubio, Gabriel
A1 Castilla-Ortega, Estela
A1 Suarez, Juan
A1 Rodriguez de Fonseca, Fernando
A1 Serrano, Antonia
A1 Pavon, Francisco Javier
K1 Lang
K1 Adult
K1 Alcohol-Related Disorders
K1 Biomarkers
K1 Brain-Derived Neurotrophic Factor
AB The identification of growth factors as potential biomarkers in alcohol addiction may help to understand underlying mechanisms associated with the pathogenesis of alcohol use disorders (AUDs). Previous studies have linked growth factors to neural plasticity in neurocognitive impairment and mental disorders. In order to further clarify the impact of chronic alcohol consumption on circulating growth factors, a cross-sectional study was performed in abstinent AUD patients (alcohol group, N = 91) and healthy control subjects (control group, N = 55) to examine plasma concentrations of brain-derived neurotrophic factor (BDNF), insulin-like growth factor-1 (IGF-1) and IGF-1 binding protein-3 (IGFBP-3). The association of these plasma peptides with relevant AUD-related variables and psychiatric comorbidity was explored. The alcohol group was diagnosed with severe AUD and showed an average of 13 years of problematic use and 10 months of abstinence at the moment of participating in the study. Regarding common medical conditions associated with AUD, we observed an elevated incidence of alcohol-induced liver and pancreas diseases (18.7%) and psychiatric comorbidity (76.9%). Thus, AUD patients displayed a high prevalence of dual diagnosis (39.3%) [mainly depression (19.9%)] and comorbid substance use disorders (40.7%). Plasma BDNF and IGF-1 concentrations were significantly lower in the alcohol group than in the control group (p<0.001). Remarkably, there was a negative association between IGF-1 concentrations and age in the control group (r = -0.52, p<0.001) that was not found in the alcohol group. Concerning AUD-related variables, AUD patients with liver and pancreas diseases showed even lower concentrations of BDNF (p<0.05). In contrast, the changes in plasma concentrations of these peptides were not associated with abstinence, problematic use, AUD severity or lifetime psychiatric comorbidity. These results suggest that further research is necessary to elucidate the role of BDNF in alcohol-induced toxicity and the biological significance of the lack of correlation between age and plasma IGF-1 levels in abstinent AUD patients.
PB Public Library of Science
YR 2017
FD 2017-10-23
LK http://hdl.handle.net/10668/11773
UL http://hdl.handle.net/10668/11773
LA en
NO García-Marchena N, Silva-Peña D, Martín-Velasco AI, Villanúa MÁ, Araos P, Pedraz M, Maza-Quiroga R, Romero-Sanchiz P, Rubio G, Castilla-Ortega E, Suárez J, Rodríguez de Fonseca F, Serrano A, Pavón FJ. Decreased plasma concentrations of BDNF and IGF-1 in abstinent patients with alcohol use disorders. PLoS One. 2017 Nov 6;12(11):e0187634
NO The present study has been supported by RETICS Red de Trastornos Adictivos (RD16/0017/ 0001) funded by Instituto de Salud Carlos III (ISCIII) and European Regional Development FundsEuropean Union (ERDF-EU); Research project funded by Ministerio de Economı´a y Competitividad and ISC-III (PI13/02261, PI16/ 01698 and PI16/01953); Research project fundedby Ministerio de Sanidad, Servicios Sociales e Igualdad and Plan Nacional sobre Drogas (PNSD 049/2013); Research project funded by Consejerı´ade Economı´a, Innovacio´n y Ciencia, Junta de Andalucı´a and ERDF-EU (CTS-433); Research projects funded by Consejerı´a de Salud y BienestarSocial, Junta Andaluc´ıa (PI0228-2013). JS, AS and FJP hold Miguel Servet research contracts funded by ISC-III and ERDF-EU (CP12/03109, CP14/00173 and CP14/00212, respectively). EC-O holds a “SaraBorrell”research contract funded by ISC-III and ERDF-EU (CD12/00455).
DS RISalud
RD Apr 7, 2025